Type I Interferon As a Biomarker in Autoimmunity and Viral Infection: a Leukocyte Subset-specific Analysis Unveils Hidden Diagnostic Options

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2017 Mar 31

PMID 28357476

Citations 10

Authors

Romy Strauss

Thomas Rose

Shaun M Flint

Jens Klotsche

Thomas Haupl

Markus Peck-Radosavljevic

Taketoshi Yoshida

Chieko Kyogoku

Alexandra Flechsig

Amy M Becker

Kathryn H Dao

Andreas Radbruch

Gerd-Rudiger Burmester

Paul A Lyons

Laurie S Davis

Falk Hiepe

Andreas Grutzkau

Robert Biesen

Affiliations

Soon will be listed here.

Abstract

Key Messages: Myeloid cells contribute more to the WBIFNS in SLE than their lymphocytic counterpart. Very similar leukocyte subsets reveal distinctive IFN signatures. IFN alpha mixes up composition of blood and leads to a preferential neutropenia, yielding relative lymphocytosis.

Citing Articles

The Contribution of Serum Sialic Acid Binding Immunoglobulin-Like Lectin 1(sSIGLEC-1) as an IFN I Signature Biomarker in the Progression of Atherosclerosis in Egyptian Systemic Lupus Erythematosus (SLE) Patients.

Nasser M, Wadie M, Farid A, Amir A Indian J Clin Biochem. 2024; 39(2):291-298.

PMID: 38577132 PMC: 10987406. DOI: 10.1007/s12291-023-01155-y.

Identification of Diagnostic Biomarkers in Systemic Lupus Erythematosus Based on Bioinformatics Analysis and Machine Learning.

Jiang Z, Shao M, Dai X, Pan Z, Liu D Front Genet. 2022; 13:865559.

PMID: 35495164 PMC: 9047905. DOI: 10.3389/fgene.2022.865559.

SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies.

Graf M, von Stuckrad S, Uruha A, Klotsche J, Zorn-Pauly L, Unterwalder N RMD Open. 2022; 8(1).

PMID: 35177553 PMC: 8860073. DOI: 10.1136/rmdopen-2021-001934.

Comparison of Surrogate Markers of the Type I Interferon Response and Their Ability to Mirror Disease Activity in Systemic Lupus Erythematosus.

Enocsson H, Wettero J, Eloranta M, Gullstrand B, Svanberg C, Larsson M Front Immunol. 2021; 12:688753.

PMID: 34276678 PMC: 8278235. DOI: 10.3389/fimmu.2021.688753.

Role of the Innate Immunity Signaling Pathway in the Pathogenesis of Sjögren's Syndrome.

Shimizu T, Nakamura H, Kawakami A Int J Mol Sci. 2021; 22(6).

PMID: 33803026 PMC: 8002742. DOI: 10.3390/ijms22063090.

References

Petri M, Wallace D, Spindler A, Chindalore V, Kalunian K, Mysler E . Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum. 2013; 65(4):1011-21. PMC: 3654174. DOI: 10.1002/art.37824. View

Sehgal K, Guo X, Koduru S, Shah A, Lin A, Yan X . Plasmacytoid dendritic cells, interferon signaling, and FcγR contribute to pathogenesis and therapeutic response in childhood immune thrombocytopenia. Sci Transl Med. 2013; 5(193):193ra89. DOI: 10.1126/scitranslmed.3006277. View

Shoshan Y, Shapira I, Toubi E, Frolkis I, Yaron M, Mevorach D . Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells. J Immunol. 2001; 167(10):5963-9. DOI: 10.4049/jimmunol.167.10.5963. View

Biesen R, Demir C, Barkhudarova F, Grun J, Steinbrich-Zollner M, Backhaus M . Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum. 2008; 58(4):1136-45. DOI: 10.1002/art.23404. View

Kabanova S, Kleinbongard P, Volkmer J, Andree B, Kelm M, Jax T . Gene expression analysis of human red blood cells. Int J Med Sci. 2009; 6(4):156-9. PMC: 2677714. DOI: 10.7150/ijms.6.156. View

Baechler E, Batliwalla F, Karypis G, Gaffney P, Ortmann W, Espe K . Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003; 100(5):2610-5. PMC: 151388. DOI: 10.1073/pnas.0337679100. View

Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S . Memory B and memory plasma cells. Immunol Rev. 2010; 237(1):117-39. DOI: 10.1111/j.1600-065X.2010.00938.x. View

Bauer J, Petri M, Batliwalla F, Koeuth T, Wilson J, Slattery C . Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum. 2009; 60(10):3098-107. PMC: 2842939. DOI: 10.1002/art.24803. View

Feng X, Wu H, Grossman J, Hanvivadhanakul P, FitzGerald J, Park G . Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum. 2006; 54(9):2951-62. DOI: 10.1002/art.22044. View

10.

Yao Y, Higgs B, Morehouse C, de Los Reyes M, Trigona W, Brohawn P . Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. Hum Genomics Proteomics. 2010; 2009. PMC: 2950308. DOI: 10.4061/2009/374312. View

11.

Bengtsson A, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H . Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus. 2001; 9(9):664-71. DOI: 10.1191/096120300674499064. View

12.

Tochizawa S, Akamatsu S, Sugiyama Y, Muraguchi M, Ohmoto Y, Ono Y . A flow cytometric method for determination of the interferon receptor IFNAR2 subunit in peripheral blood leukocyte subsets. J Pharmacol Toxicol Methods. 2004; 50(1):59-66. DOI: 10.1016/j.vascn.2004.02.003. View

13.

Soza A, Everhart J, Ghany M, Doo E, Heller T, Promrat K . Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002; 36(5):1273-9. DOI: 10.1053/jhep.2002.36502. View

14.

Samarajiwa S, Forster S, Auchettl K, Hertzog P . INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res. 2008; 37(Database issue):D852-7. PMC: 2686605. DOI: 10.1093/nar/gkn732. View

15.

Kalunian K, Merrill J, Maciuca R, McBride J, Townsend M, Wei X . A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2015; 75(1):196-202. DOI: 10.1136/annrheumdis-2014-206090. View

16.

Lyons P, McKinney E, Rayner T, Hatton A, Woffendin H, Koukoulaki M . Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis. Ann Rheum Dis. 2009; 69(6):1208-13. PMC: 2935323. DOI: 10.1136/ard.2009.108043. View

17.

Bennett L, Palucka A, Arce E, Cantrell V, Borvak J, Banchereau J . Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197(6):711-23. PMC: 2193846. DOI: 10.1084/jem.20021553. View

18.

Preble O, Rothko K, Klippel J, Friedman R, Johnston M . Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon. J Exp Med. 1983; 157(6):2140-6. PMC: 2187063. DOI: 10.1084/jem.157.6.2140. View

19.

von Wussow P, Jakschies D, Hochkeppel H, Horisberger M, Hartung K, Deicher H . MX homologous protein in mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. 1989; 32(7):914-8. View

20.

Petri M, Singh S, Tesfasyone H, Dedrick R, Fry K, Lal P . Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 2009; 18(11):980-9. PMC: 4752166. DOI: 10.1177/0961203309105529. View